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Abstract
Dysfunctional regulation of airway smooth muscle tone is a feature of obstructive airway diseases such as asthma and chronic obstruc-
tive pulmonary disease. Airway smooth muscle contraction is directly associated with changes in the phosphorylation of myosin light
chain (MLC), which is increased by Rho and decreased by Rac. Although cyclic adenosine monophosphate (cAMP)-elevating agents are
believed to relieve bronchoconstriction mainly via activation of protein kinase A (PKA), here we addressed the role of the novel cAMP-
mediated exchange protein Epac in the regulation of airway smooth muscle tone. Isometric tension measurements showed that specific
activation of Epac led to relaxation of guinea pig tracheal preparations pre-contracted with methacholine, independently of PKA. In air-
way smooth muscle cells, Epac activation reduced methacholine-induced MLC phosphorylation. Moreover, when Epac was stimulated,
we observed a decreased methacholine-induced RhoA activation, measured by both stress fibre formation and pull-down assay whereas
the same Epac activation prevented methacholine-induced Rac1 inhibition measured by pull-down assay. Epac-driven inhibition of both
methacholine-induced muscle contraction by Toxin B-1470, and MLC phosphorylation by the Rac1-inhibitor NSC23766, were signifi-
cantly attenuated, confirming the importance of Rac1 in Epac-mediated relaxation. Importantly, human airway smooth muscle tissue
also expresses Epac, and Epac activation both relaxed pre-contracted human tracheal preparations and decreased MLC phosphoryla-
tion. Collectively, we show that activation of Epac relaxes airway smooth muscle by decreasing MLC phosphorylation by skewing the
balance of RhoA/Rac1 activation towards Rac1. Therefore, activation of Epac may have therapeutical potential in the treatment of
obstructive airway diseases.
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Introduction
Airway hyper-responsiveness is generally associated with 
exaggerated bronchoconstriction, a key feature of a number of
obstructive airway diseases, including asthma and chronic
obstructive pulmonary disease [1, 2]. Airway smooth muscle tone
is regulated by actin-myosin interactions through the phosphory-
lation of the 20 kD regulatory myosin light chain (MLC) [3], which
in turn results from the dynamic balance between MLC kinase and
MLC phosphatase activities [3, 4]. Actin-myosin dynamics in
fibroblasts, epithelial and airway smooth muscle cells are tightly
regulated by the Rho GTPase family members RhoA and Rac1
[5–7]. In particular, RhoA is involved in the formation and mainte-
nance of stress fibres, which are contractile structures consisting
of bundles of actin and myosin filaments that regulate tension
development [8]. Moreover, activation of RhoA leads to airway
smooth muscle tissue contraction [9, 10] mainly via the inhibition
of MLC phosphatase, leading to increased MLC phosphorylation
[11, 12]. On the other hand, Rac1 activates p21-activated kinase,
which phosphorylates and inhibits MLC kinase, leading to reduced
MLC phosphorylation [13, 14]. Hence, given their opposing
effects on MLC phosphorylation, cross-talk between and comple-
mentary regulation of RhoA and Rac1 is likely an important deter-
minant of airway smooth muscle tone.
cAMP-elevating agents, such as 2-adrenoceptor agonists, are
potent inhibitors of bronchial constriction. Although used clinically
for many years to induce airway smooth muscle relaxation, their
precise mechanism of action is not yet completely clear [15, 16].
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Classically, activation of cAMP-mediated effector protein kinase A
(PKA) is believed to be involved in airway smooth muscle relax-
ation [16]. In fact, PKA phosphorylates several target proteins that
regulate airway smooth muscle tone, including MLC kinase and
potassium channels [17–19]. However, using selective inhibitors
of PKA, Spicuzza et al. [20] demonstrated that 2-adrenoceptor-
mediated relaxation of guinea pig airway smooth muscle is PKA
independent. Importantly, alternative mechanisms have not been
identified yet. A better understanding of these mechanisms would
help to define more specific targets for pharmacological treatment
of obstructive airway diseases. In this regard, exchange proteins
directly activated by cAMP (Epac) have recently been discovered
and identified as novel cAMP sensors able to elicit, alone or in
concert with PKA, several biological effects attributed to intracel-
lular cAMP [21–25]. Two isoforms of Epac (Epac1 and Epac2)
have been described and partly characterized with respect to their
subcellular localization, structure, and function [21, 26]. Although
initially characterized as Rap1-specific guanine nucleotide
exchange factors (GEFs) [21, 22], Epac proteins are also able to
activate a number of small GTPases that affect a variety of biolog-
ical processes [26]. Recent studies using human pulmonary
artery endothelial cells show that Epac regulates endothelial
integrity and permeability by inhibiting Rho and stimulating Rac
[27, 28]. We have recently shown that both Epac1 and Epac2 are
expressed in human airway smooth muscle cells [29]. Moreover,
using the selective Epac activators in combination with PKA acti-
vators and inhibitors, we also demonstrated that both Epac and
PKA modulate cytokine release by human airway smooth muscle
cells in vitro [29].
In the present study, we assessed whether Epac proteins rep-
resent a functional effector pathway for cAMP-mediated airway
smooth muscle relaxation. We show that Epac induces airway
smooth muscle relaxation in guinea pig and human tracheal tissue
by shifting the relative balance of pro-contractile RhoA and con-




Methacholine hydrochloride was from ICN Biomedicals (Costa Mesa, CA,
USA). NSC23766 was from Tocris Biosciences (Bristol, UK). 6-Bnz-cAMP,
8-pCPT-2-O-Me-cAMP (CPT, chlorophenylthio), Rp-8-CPT-cAMPS and
Sp-8-pCPT-2-O-Me-cAMPS were from BIOLOG Life Science Institute
(Bremen, Germany). The (–)-isoproterenol hydrochloride, histamine dihy-
drochloride and protease inhibitors and secondary antibodies were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). foetal bovine serum
(FBS) was from Hyclone Thermo Scientific (Waltham, MA, USA). Other
components of the cell culture medium were obtained from Gibco BRL Life
Technologies (Paisley, UK). The antibodies against vasodilator-stimulated
phosphoprotein (VASP) and Rac1 were obtained from Cell Signaling
Technology (Beverly, MA, USA) and Millipore (Billerica, MA, USA), respec-
tively. The antibodies against RhoA and phospho and total MLC were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against Epac1
and Epac2 were kindly provided by Dr. J. L. Bos (University Medical Center
Utrecht, The Netherlands) [30]. Clostridium difficile toxin B-1470 was
kindly provided by Drs. C. von Eichel-Streiber and H. Genth (University of
Mainz, Germany). Alexa Fluor 488 phalloidin was from Invitrogen (Eugene,
OR, USA). All chemicals used were of analytical grade.
Guinea pig tissue and cell isolation
Outbred specific pathogen-free male Dunkin Hartley guinea pigs (Harlan-
Hillcrest, UK) (800–1200 g) were used. The animals were killed by experi-
mental concussion followed by rapid exsanguinations. The trachea was
removed from the larynx to the bronchi and rapidly placed in a
Krebs–Henseleit (KH) solution (composition in mM: NaCl 117.50; KCl 5.60;
MgSO4 1.18; CaCl2 2.50; NaH2PO4 1.28; NaHCO3 25.0 and D-glucose 5.50;
pH 7.4) at 37C, gassed with 95% O2 and 5% CO2. All protocols described
in this study were approved by the University of Groningen Committee for
Animal Experimentation. The trachea was prepared free of serosal connec-
tive tissue in gassed KH solution. For the relaxation studies, single tracheal
open-ring preparations were mounted for isometric recording. For Western
blot analysis of VASP and Rac1, guinea pig tracheae were pulverized under
liquid nitrogen after stimulation, followed by sonication in Ripa buffer
(composition: 50 mM Tris HCl, 150 mM NaCl, 1 mM ethylenediaminete-
traacetic acid, 1% Igepal and 0.25% Na-deoxycholate, pH 7.4) supple-
mented with 10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin,
1 mM Na3VO4, 1 mM NaF and 1 mM PMSF. For the isolation of guinea pig
tracheal smooth muscle cells, the epithelium-denuded airway smooth
muscle layer was removed from the trachea, chopped by using a McIlwain
tissue chopper and transferred to a culture flask. Cells were grown on
DMEM  10% FBS.
Human airway smooth muscle tissue 
and cell isolation
Human tracheal sections from anonymized lung transplantations donors
were obtained from the Department of Cardiothoracic Surgery, University
Medical Centre Groningen. Human airway tissue was rapidly transported to
the laboratory in pre-gassed KH solution. After careful removal of mucosa
and connective tissue and dissection of the smooth muscle layer, tracheal
smooth muscle strips were prepared with macroscopically identical length
and width and mounted for isometric recording. Airway smooth muscle
strips were also pulverized and used for Western blot analysis of Epac
expression. In addition, primary human tracheal smooth muscle cells were
isolated from the epithelium-denuded airway smooth muscle layer using the
same protocol described for guinea pig airway smooth muscle samples.
Isometric tension measurements
Single guinea pig tracheal open-ring preparations or human airway smooth
muscle strips were connected to an isometric force-displacement trans-
ducer (Grass FT03) using surgical wire and the resting tension was
adjusted to 0.5 g. After a 60 min. equilibration period with three washes,
the preparations were contracted with cumulative administration of metha-
choline (0.1, 1, 10 M), followed by washout. Thereafter, basal tone was
© 2011 The Authors
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assessed using isoproterenol (1 M) and tension was re-adjusted to 0.5 g.
Subsequently, the preparations were contracted with methacholine (0.1, 1,
10 and 100 M). After three additional washouts, tracheal preparations
were pre-incubated for 30 min. with the selective PKA inhibitor Rp-8-CPT-
cAMPS (100 M) or vehicle (KH buffer) and pre-contracted with metha-
choline (0.3 M for guinea pig tissue, 50% effect of 100 M for human
tissue) or histamine (3 M). Cumulative concentration-response curves
were constructed using the 2-adrenoceptor agonist isoproterenol
(109–106 M), the specific Epac activators 8-pCPT-2-O-Me-cAMP and
Sp-8-pCPT-2-O-Me-cAMPS (108–3 . 104 M; both) or the PKA activator
6-Bnz-cAMP (108–3 . 104 M). All cumulative concentration-response
curves were constructed in 0.5 log increments. After washout, basal tone
was re-assessed using isoproterenol (10 M). To study the role of small
GTPases in Epac-mediated effects, guinea pig open-ring preparations were
incubated overnight with Clostridium difficile toxin B-1470 (0.1 ng/ml) or
vehicle (0.1% FBS) in DMEM. The next day, the rings were thoroughly
washed with fresh KH solution and mounted for isometric contraction.
Toxin-induced glucosylation of Ras-like GTPases was monitored by
immunoblotting using a specific anti-Rac1 antibody [29].
Cell culture
Guinea pig and human primary airway smooth muscle cells and the
immortalized human airway smooth muscle cell line (hTERT) were grown
in DMEM supplemented with streptomycin, penicillin and 10% FBS. hTERT
airway smooth muscle cells were prepared as described previously [29,
31]. All procedures were approved by the human Research Ethics Board of
the University of Manitoba [32]. For all experiments, cells were grown to
100% confluency and serum deprived for 24 hrs. Medium was refreshed
every 48–72 hrs. Upon reaching confluency, cells were passaged by
trypsinization. In the present study, passages 1–5 were used for primary
guinea pig and human airway smooth muscle cells and passages 1 to 30
for hTERT airway smooth muscle cells.
Rac1 and RhoA pull-down, phosphorylation 
of VASP/MLC and immunoblot analysis
The amount of activated Rac1 or RhoA was measured with the pull-down
technique by using glutathione S-transferase tagged PAK1 or Rhothekin,
respectively, as previously described [33, 34]. The level of activated
GTPases was normalized to Rac1 or RhoA content in total cell lysates,
respectively. For the measurement of the phosphorylation of VASP and
MLC, cells or tissue strips were stimulated with methacholine (100 M), 8-
pCPT-2-O-Me-cAMP (300 M) or their combination in the absence or
presence of the PKA inhibitor Rp-8-CPT-cAMPS (100 M) or the Rac1
inhibitor NSC23766 (100 M). Subsequently, cells were lysed in supple-
mented Ripa buffer, and tissue rings and strips were pulverized under liquid
nitrogen followed by sonication in Ripa buffer. Protein concentration was
determined by Pierce measurement. Equal amounts of protein were loaded
on 8–15% polyacrylamide gels and analysed for the protein of interest by
using the specific primary antibody (dilution anti-Epac1, anti-Epac2, anti-
Rac1 and anti-VASP, 1:500 all; anti-phospho-MLC, total MLC 1:200 each;
anti Rho-A, 1:100; anti--actin, 1:2000) and the secondary HRP-conjugated
antibody (dilution 1:2000 anti-rabbit, 1:3000 antimouse and 1:10,000 anti-
goat). Protein bands were subsequently visualized on film using western
lightning plus-ECL (PerkinElmer Inc., Waltman, MA, USA) and quantified by
densitometry using TotalLab software (Nonlinear Dynamics, Newcastle,
UK). Results were normalized to specific control proteins.
Fluorescence staining
Guinea pig airway smooth muscle cells were plated on Lab-Tek™ Chamber
Slides (Thermo Scientific) and treated with methacholine (100 M) and/or
8-pCPT-2-O-Me-cAMP (300 M), fixed in 3% formaldehyde solution in
Hank’s Buffered Salt Solution (HBSS) for 15 min. at room temperature
(RT), washed and permeabilized with 0,05% Triton X-100 in HBSS for 
2 min. at RT. Stress fibres were stained with Alexa Fluor 488 phalloidin 
(15 min. at RT). After staining, cover slips were mounted using ProLong
Gold antifade reagent (Invitrogen) and they were analysed by using an
Olympus AX70 microscope equipped with digital image capture system
(ColorView Soft System with Olympus U CMAD2 lens; Olympus, Essex, UK).
Data analysis
The effects of isoproterenol and the cAMP analogues were expressed as
percentages of methacholine-induced tone. The effect of the highest con-
centration of methacholine used was defined as Emax. Using this Emax,
the sensitivity to the different substances was evaluated as pEC50 (–log
EC50). All data represent means  S.E.M. from n separate experiments.
The statistical significance of differences between data was determined by
a paired or unpaired Student’s t-test when appropriate. Differences were
considered to be statistically significant when P 	 0.05.
Results
Epac induces relaxation of guinea pig tracheal
smooth muscle preparations
To activate PKA and Epac, we used two well-described cAMP 
analogues, known for their selectivity towards the distinct cAMP
effectors [29, 35]. 6-Bnz-cAMP is a selective activator of PKA,
which has been used to unravel PKA signalling in several systems
including the airways [36, 37]. An index of PKA activation is the
phosphorylation of its specific substrate VASP [38]. As expected,
treatment of guinea pig tracheal rings with the PKA selective 
activator 6-Bnz-cAMP (P 	 0.01) or with the 2-receptor agonist,
isoproterenol (P 	 0.01), induced significant phosphorylation of
VASP compared to basal levels (Fig. 1A). Moreover, VASP 
phosphorylation by direct PKA activation or via 2-receptor was
prevented by Rp-8-CPT-cAMPS (P 	 0.05 for both, Fig. 1A), a
selective inhibitor of both type I and type II of PKA [39]. Similar
results were observed in isolated guinea pig airway smooth muscle
cells (not shown). These data both confirm that isoproterenol-
induced cAMP activates PKA, and the specificity of PKA-mediated
VASP phosphorylation.
We next investigated the functional importance of isoproterenol-
induced PKA activation in regulating airway smooth muscle tone.
© 2011 The Authors
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Fig. 1 Isoproterenol-induced relaxation of guinea
pig tracheae. Impact of PKA. (A) Guinea pig tra-
cheal open rings were treated without (Control)
and with 100 M Rp-8-CPT-cAMPS for 30 min.,
followed by addition of 1 M isoproterenol or 
500 M 6-Bnz-cAMP for 15 min. Phosphorylation
of the PKA effector VASP was evaluated by using
a VASP-specific antibody which recognizes both
phospho-VASP (p-VASP, upper band) and non-
phospho-VASP (VASP, lower band). Representative
blots are shown. Graphs depict the ratio between
phospho-VASP and total VASP (phospho- 
non-phospho-VASP) expressed in percentage of
isoproterenol-treated conditions. Equal loading
was verified by analysis of -actin. Results are
mean  S.E.M. of seven to nine independent
experiments. (B) Cumulative concentration
response curves of isoproterenol-induced relax-
ation of guinea pig tracheal open ring preparations
pre-contracted with 0.3 M methacholine in the
absence (Control) and presence of 100 M Rp-8-
CPT-cAMPS. Results are means  S.E.M. of six
independent experiments. **P 	 0.01 compared
to basal control; #P 	 0.05; compared to basal.
Table 1 Effects of isoproterenol and specific analogues of cAMP on pre-contracted guinea pig and human tracheal preparations with or without
treatment with Rp-8-CPT-cAMPS or toxin B-1470
Treatment Emax (% of methacholine) pEC50-log (M) n
Guinea pig trachea
Isoprenaline Control 99.6  0.40 8.10  0.05 6
Rp-8-CPT-cAMPS 101.3  1.50 7.95  0.06* 6
8-pCPT-2-O-Me-cAMP Control 64.6  4.20 4.18  0.08 8
Rp-8-CPT-cAMPS 56.8  7.00 4.20  0.08 5
Vehicle 72.3  2.50 4.50  0.06 5
Toxin B-1470 57.4  2.40 4.29  0.07 5
Sp-8-pCPT-2-O-Me-cAMPS Control 72.1  3.90 4.58  0.13# 3
6-Bnz-cAMPS Control 77.3  6.80 3.90  0.04 4
Human trachea
8-pCPT-2-O-Me-cAMP Control 63.9  3.65 5.26  0.29 4
Rp-8-CPT-cAMPS 55.8  7.20 5.60  0.41 3
The Emax (in% relaxation) and the pE50-values for isoproterenol, 8-pCPT-2-O-Me-cAMP, 6-Bnz-cAMP and Sp-8-pCPT-2-O-Me-cAMP in guinea pig
and/or human tracheal preparations pre-contracted with methacholine in the absence or presence of the PKA inhibitor Rp-8-CPT-cAMPS (100 M)
or after overnight treatment with vehicle or toxin B-1470 (0.1 ng/ml). Data represent means  S.E.M. of n experiments.
J. Cell. Mol. Med. Vol 15, No 7, 2011
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Treatment of guinea pig tracheal open ring preparations with 
isoproterenol resulted in a dose-dependent relaxation of metha-
choline-induced tone (Fig. 1B, Table 1). Interestingly, pre-treatment
of the same preparations with the PKA inhibitor Rp-8-CPT-cAMPS
induced only a small rightward shift of the isoproterenol concen-
tration-response curve (Fig. 1B, Table 1), indicating only a modest
role for PKA in 2-receptor-mediated airway smooth muscle relax-
ation. Nonetheless, we confirmed that direct activation of PKA
with 6-Bnz-cAMP did induce airway smooth muscle relaxation of
guinea pig open rings pre-contracted with methacholine (Table 1).
Collectively, these data strongly suggest that though PKA can 
suppress contractile tone of airway smooth muscle, it may not 
be the principal effector pathway engaged during 2-receptor-
mediated relaxation.
Because isoproterenol-induced airway smooth muscle 
relaxation appears to occur largely independent of PKA, other
cAMP activated pathways could be involved. We suggested an
important role for Epac in airway smooth muscle relaxation. We
observed that both Epac1 and Epac2 proteins are constitutively
expressed in guinea pig tracheae (Fig. 2A). To examine the role
of Epac in regulating airway smooth muscle tone, we used the
cAMP analogue 8-pCPT-2-O-Me-cAMP, which is a well-recog-
nized Epac selective activator [35, 40]. By means of this com-
pound, novel intriguing functions of Epac in the airways have
been unravelled [24, 29, 36, 37]. The methylated structure of 8-
pCPT-2-O-Me-cAMP makes it an extremely poor PKA activator
and allows for specific discrimination between both cAMP-acti-
vated signalling pathways [35, 40]. Treatment with 8-pCPT-2-O-
Me-cAMP relaxed guinea pig tracheal open-rings pre-contracted
with methacholine (Fig. 2B, Table 1) or histamine (not shown) in
a dose-dependent fashion. The effect of Epac on muscle tone
was selective as the PKA inhibitor Rp-8-CPT-cAMPS had no
impact on Epac-induced airway smooth muscle relaxation 
(Fig. 2B, Table 1). The specificity of 8-pCPT-2-O-Me-cAMP was
© 2011 The Authors
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Fig. 2 Impact of Epac activation on methacholine-
induced contraction of guinea pig tracheae. (A)
Expression of Epac1 and Epac2 in guinea pig tra-
cheal homogenates. (B) Cumulative concentration
response curves of 8-pCPT-2-O-Me-cAMP and
Sp-8-pCPT-2-O-Me-cAMPS on methacholine
(0.3 M) pre-contracted guinea pig tracheal open
ring preparations in the absence (Control) or
presence of 100 M Rp-8-CPT-cAMPS. Results
are means  S.E.M. of three to eight independent
experiments. (C) Effects of 1 M isoproterenol,
500 M 6-Bnz-cAMP or 300 M 8-pCPT-2-O-
Me-cAMP on the phosphorylation of VASP in
guinea pig tracheal open rings in the absence and
presence of 100 M Rp-8-CPT-cAMPS. Equal
loading was verified by analysis of -actin.
Representative immunoblots are shown together
with densitometric quantifications of the percent-
age of phospho-VASP compared to control.
Results are means  S.E.M. of five independent
experiments.
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further confirmed by the inability of the Epac activator to
increase phosphorylation of VASP (Fig. 2C). To further confirm
the importance of Epac in regulating airway smooth muscle
tone, we used Sp-8-pCPT-2-O-Me-cAMPS, a selective Epac
activator which is more resistant to phosphodiesterase hydroly-
sis, compared to 8-pCPT-2-O-Me-cAMP [41]. Indeed we
observed that Sp-8-pCPT-2-O-Me-cAMPS dose-dependently
reduced methacholine-induced tone of guinea pig tracheal open
rings (Fig. 2B, Table 1). Of note, sensitivity (pEC50) to phosphodi-
esterase-resistant Sp-8-pCPT-2-O-Me-cAMPS was significantly
greater than that we measured for 8-pCPT-2-O-Me-cAMPS 
(Table 1). Taken together, these findings clearly show that activa-
tion of Epac induces guinea pig airway smooth muscle relaxation
independent of PKA.
Epac reduces the phosphorylation of MLC 
by modulating the Rac1/RhoA balance
Actin-myosin dynamics and airway smooth muscle tone are 
regulated by phosphorylation of MLC. Therefore, we studied the
effect of Epac stimulation on (agonist-induced) MLC phosphoryla-
tion in both guinea pig and hTERT airway smooth muscle cells. 
As expected, treatment with methacholine increased the phospho-
rylation of regulatory MLC in both guinea pig airway smooth 
muscle cells (Fig. 3A) (P 	 0.001) and hTERT airway smooth
muscle cells (Fig. 3B) (P 	 0.01). Importantly, 8-pCPT-2-O-Me-
cAMP completely prevented the induction of MLC phosphorylation
by methacholine in both cell types (P 	 0.01 for guinea pig and
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 Activation of Epac inhibits methacholine-induced phosphorylation of MLC. (A) Guinea pig and (B) hTERT-airway smooth muscle cells were stimu-
lated for 30 min. with 100 M methacholine, 300 M 8-pCPT-2-O-Me-cAMP or their combination and MLC phosphorylation (p-MLC) was evaluated by
Western blot. p-MLC levels were normalized to -actin. Representative blots for p-MLC and -actin are shown. Graphs represent the results of four to
seven independent experiments. *P 	 0.05; ***P 	 0.001 compared to basal control; ##P 	 0.01 compared to methacholine.
J. Cell. Mol. Med. Vol 15, No 7, 2011
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P 	 0.05 for hTERT airway smooth muscle cells), whereas the
Epac activator did not affect basal phospho-MLC levels (Fig. 3A
and B). No differences were observed in the levels of total MLC for
the different treatments (not shown). These observations suggest
a regulatory role for Epac in contractile agonist-induced actin-
myosin activation, but a modest role in resting (basal) conditions.
The phosphorylation of MLC is partly regulated by the 
balance between RhoA and Rac1 activation. Therefore, we next
studied the effect of methacholine on the activation of RhoA and
Rac1, and assessed the effect of co-activation of Epac with 
8-pCPT-2-O-Me-cAMP on these responses in guinea pig and
hTERT airway smooth muscle cells. The activation of RhoA was
evaluated by two independent indices: the formation of stress
fibres, and GTP-loading of RhoA. Rac1 activation was similarly
evaluated by measuring GTP-loading of Rac1. Methacholine
induced stress fibre formation (P 	 0.001, Fig. 4A) and increased
GTP-loading of RhoA (P	 0.01, Fig. 4B), whereas Rac1 activation
was suppressed, as GTP-loading of Rac1 was reduced compared
to basal levels (P 	 0.05, Fig. 4C). Importantly, concomitant acti-
vation of Epac with 8-pCPT-2-O-Me-cAMP diminished metha-
choline-induced stress fibre formation (P	 0.001, Fig. 4A) as well
as GTP-loading of RhoA (P 	 0.01, Fig. 4B), whereas basal RhoA
activity was not affected by the Epac activator (Fig. 4A). On the
other hand, the impaired Rac1 activity after methacholine treat-
ment was completely prevented by co-treatment with 8-pCPT-2-
O-Me-cAMP (P 	 0.05, Fig. 4C).
Taken together, these findings indicate that Epac stimulation
relaxes methacholine-induced airway smooth muscle tone via
shifting the relative activation of RhoA and suppression of Rac1
in such a way that an equilibrium favouring Rac1 is established,
which in turn results in a reduced MLC phosphorylation. To con-
firm that activation of Rac1 by Epac is indeed important for its
relaxant properties, guinea pig tracheal rings were incubated
overnight with Clostridium difficile toxin B-1470. Toxin B-1470 is
known to inhibit Epac substrate GTPases such as Rac1 by
monoglucosylation, but not RhoA [42], and therefore can pro-
vide insight concerning the relative importance of Rac1 and
RhoA regulation by Epac in the methacholine-induced contrac-
tion. The effectiveness of toxin B-1470 in inhibiting GTPases in
guinea pig tracheae was studied by immunoblotting analysis
using a specific antibody against the small GTPase Rac1 that
only recognizes the non-glucosylated epitope of Rac1 [29].
Overnight treatment of guinea pig tracheal smooth muscle tissue
with toxin B-1470 inactivated approximately 50% of total 
Rac1 (P 	 0.05), as illustrated by the reduced expression of
non-glycosylated Rac1 (Fig. 5A). Incubation of guinea pig
smooth muscle preparations with toxin B-1470 did not alter the
active tension generated by 0.3 M concentration of metha-
choline (1.37  0.17 g of control versus 1.35  0.23 g for toxin
B-1470). Importantly, the same treatment significantly reduced
the relaxant effect of the Epac activator 8-pCPT-2-O-Me-cAMP
on methacholine-induced airway smooth muscle contraction
(Fig. 5B, Table 1) (P 	 0.05), demonstrating that Epac-mediated
airway smooth muscle relaxation relies, in part, on the ability of
8-pCPT-2-O-Me-cAMP to activate Rac1.
To confirm the importance of Rac1 in the Epac-mediated
effects the selective Rac1-inhibitor NSC23766, was used.
NSC23766 prevents Rac1 activation by Rac-specific GEFs TrioN
and Tiam1, without interfering with the activation of the other
Rho-like GTPases (Rho and Cdc42) and has been used to study
the functional role of Rac1 [43]. Inhibition of Rac1 augmented
basal MLC phosphorylation (P	 0.05, Fig. 5C) which was not fur-
ther increased by methacholine (Fig. 5C), in line with the inhibitory
effect of methacholine on Rac1 activity (Fig. 4C). Importantly, in
the presence of NSC23766, 8-pCPT-2-O-Me-cAMP was unable to
reduce MLC phosphorylation (Fig. 5C). Collectively, these findings
indicate that activation of Rac1 by Epac plays an important role in
Epac-mediated inhibition of MLC phosphorylation and relaxation
of airway smooth muscle.
Epac reduces airway smooth muscle tone and MLC
phosphorylation in human tracheae
We confirmed our key findings in guinea pig in freshly isolated
human airway smooth muscle strips and cells. Western analysis
revealed that both Epac1 and Epac2 are constitutively expressed in
human tracheal smooth muscle strips (Fig. 6A). Importantly, 
treatment with the Epac activator 8-pCPT-2-O-Me-cAMP dose-
dependently reduced methacholine-induced contraction of human
tracheal strip preparations (Fig. 6B, Table 1). Treatment with the
PKA inhibitor Rp-8-CPT-cAMPS did not affect 8-pCPT-2-O-Me-
cAMP-mediated relaxations (Fig. 6A, Table 1), confirming a 
PKA-independent effect for Epac proteins. Accordingly, activation
of Epac did not induce VASP phosphorylation by PKA in human
tracheal preparations (Fig. 6C). As expected, isoprotenerol and
PKA activation with 6-Bnz-cAMP did induce phosphorylation of
VASP in human airway smooth muscle cells (Fig. 6C and D) (P 	
0.01), which was largely inhibited by co-treatment with selective
PKA inhibition using Rp-8-CPT-cAMPS (Fig. 6D) (P 	 0.05 both).
Importantly, methacholine induced a ~3-fold increase of phospho-
rylation of MLC (P 	 0.001), effect that was completely reversed
by co-treatment with 8-pCPT-2-O-Me-cAMP to activate Epac 
(Fig. 6E) (P 	 0.05). As we observed for guinea pig cells, basal
levels of phosphorylated MLC were not affected by 8-pCPT-2-O-
Me-cAMP and no differences were observed in the levels of total
MLC for the different treatments (Fig. 6E). Taken together, these
finding demonstrate that activation of Epac proteins induce relax-
ation of human airway smooth muscle, independent of PKA, by
inhibiting agonist-induced MLC phosphorylation.
Discussion
Our study is the first to show activation of cAMP-dependent Epac
as a novel signalling effector that promotes relaxation of airway
smooth muscle. Here, we demonstrate that Epac activation inhibits
contraction of airway smooth muscle from guinea pig and human
by a process that is largely independent of PKA. Importantly, we
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
1558 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 Activation of Epac shifts the balance between RhoA and Rac1 towards Rac1. Guinea pig or hTERT-airway smooth muscle cells were stimulated for
30 min. with 100 M methacholine, 300 M 8-pCPT-2-O-Me-cAMP or their combination. (A) Stress fibre formation was measured by phalloidin stain-
ing in guinea pig airway smooth muscle. Results are expressed as percentage of stress fibre-positive cells relative to the total number of cells.
Representative images of five experiments are shown. (B) In hTERT-airway smooth muscle cells, GTP-loaded RhoA and total RhoA, and (C) GTP-loaded
Rac1 and total Rac1 were determined as described in ‘Materials and Methods’. Representative blots of three to five independent experiments are shown.
Densitometric quantifications depicts GTP-loaded RhoA and Rac1 in percentage of control. *P 	 0.05; **P 	 0.01; ***P 	 0.001 compared to basal
control; #P 	 0.05; ##P 	 0.01; ###P 	 0.001 compared to methacholine alone.
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found that Epac proteins shift the balance between Rac1 and RhoA
activation during agonist-induced contraction in favour of Rac1,
resulting in reduction of MLC phosphorylation and subsequent
inhibition of airway smooth muscle contraction (Fig. 7).
Abnormal regulation of airway smooth muscle tone causes air-
way hyper-responsiveness, a main feature of obstructive airway
diseases such as asthma and chronic obstructive pulmonary dis-
ease [2]. The complex mechanisms of airway tone regulation rely
on the intrinsic capacity of the airway smooth muscle to contract
and to relax providing control of airway lumen diameter and 
respiratory capacity. The relaxant properties of cAMP-elevating
2-agonists are well established [15], but there is surprisingly 
little precise knowledge about the molecular mechanisms of 
cAMP action. Spicuzza et al. [20] have reported on the existence
© 2011 The Authors
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Fig. 5 Impairment of relaxant properties of the Epac activator 8-pCPT-2-O-Me-cAMP by Rac1-inhibition. (A) Immunoreactivity of Rac1 in guinea pig tra-
chea homogenates after overnight treatment with vehicle or with 0.1 ng/ml toxin B-1470 was measured by Western blot. Equal loading was verified by
analysis of -actin. Representative immunoblots are shown with the quantifications of four independent experiments. (B) Guinea pig tracheal ring prepa-
rations were incubated overnight with vehicle or 0.1 ng/ml toxin B-1470. Cumulative concentration response curves of 8-pCPT-2-O-Me-cAMP-induced
relaxation of guinea pig tracheal ring preparations pre-contracted with 0.3 M methacholine are shown. Results are means  S.E.M. of five independent
experiments. (C) hTERT-airway smooth muscle cells were pre-treated with the Rac1 inhibitor NSC23766 (100 M) for 30 min. and then stimulated for
additional 30 min. with methacholine (100 M) alone or in combination with 8-pCPT-2-O-Me-cAMP (300 M). MLC phosphorylation (p-MLC) was eval-
uated by Western blot and normalized to -actin. Representative blots are shown. Graphs represent the results of six to eight independent experiments.
*P 	 0.05; **P 	 0.01 compared to basal control; #P 	 0.05 compared to methacholine.
1560 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 6 Activation of Epac by 8-pCPT-2-O-Me-cAMP induces relaxation of human tracheal smooth muscle strips. (A) Expression of Epac1 and Epac2 in
human tracheal smooth muscle homogenates using two protein contents. (B) Cumulative concentration response curves of 8-pCPT-2-O-Me-cAMP-
induced relaxation of human tracheal smooth muscle strips pre-contracted with 0.1 M methacholine in the absence and presence of 100 M Rp-8-CPT-
cAMPS. Results are means  S.E.M. of three independent experiments. (C) and (D) Effects of 1 M isoproterenol, 500 M 6-Bnz-cAMP or 300 M 
8-pCPT-2-O-Me-cAMP on phosphorylation of VASP in primary human tracheal smooth muscle cells in the absence and presence of 100 M Rp-8-CPT-
cAMPS. Results are mean  S.E.M. of five to seven independent experiments. Graphs depict the ratio between phospho-VASP and total VASP (phospho- 
non-phospho-VASP) expressed in percentage of isoproterenol-treated conditions. Equal loading was verified by analysis of -actin. (E) Effect of 300 M
8-pCPT-2-O-Me-cAMP on methacholine-induced phosphorylation of MLC in primary human tracheal smooth muscle cells. p-MLC levels were normal-
ized to -actin. Representative blots of p-MLC, total MLC and -actin are shown. Graphs represent the results of three to six independent experiments.
**P 	 0.01; ***P 	 0.001; compared to basal control; #P 	 0.05 compared to methacholine.
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of PKA-independent mechanisms of an unknown nature in the iso-
proterenol-induced relaxation of guinea pig tracheae [20]. In this
study, we confirm that although isoproterenol activates PKA, iso-
proterenol-induced airway smooth muscle relaxation occurs
largely independent of PKA, being refractory to the PKA inhibitor
Rp-8-CPT-cAMPS. Unfortunately, the exact role of Epac in 2-ago-
nists-induced airway smooth muscle relaxation remains difficult
to assess due to the lack of specific Epac inhibitors. Although PKA
does have anti-spasmogenic effect, as shown by the capacity of
the specific PKA activator 6-Bnz-cAMP to relax airway smooth
muscle, our study identifies the novel cAMP-regulated Epac as a
novel mediator of airway smooth muscle relaxation.
This conclusion is consistent with a growing body of data
focused on Epac, showing these proteins to be significant contrib-
utors to responses previously solely associated with PKA activa-
tion [21, 26]. Interestingly, recent reports have indicated that Epac
proteins modulate contractile function in cardiac and vascular
muscle tissues [44, 45]. Moreover, they seem able to regulate
contractile myofilament function [44] and potassium channels
[46, 47], processes which may be also important in the contrac-
tile response of airway smooth muscle as well. Indeed, by selec-
tive activation or inhibition of PKA and Epac signalling, we have
recently elucidated the relative contribution of the two cAMP-
mediated effectors in the synthetic function of airway smooth
muscle [29]. Here, we show a role for Epac in the regulation of air-
way smooth muscle tone in both guinea pigs and human beings.
The Epac-specific cAMP analogues 8-pCPT-2-O-Me-cAMP and
Sp-8-pCPT-2-O-Me-cAMPS cause relaxation of guinea pig and
human airway smooth muscle preparations pre-contracted with
histamine or methacholine. Importantly, the relaxant properties of
8-pCPT-2-O-Me-cAMP on methacholine-induced contraction
were not affected by the PKA inhibitor Rp-8-CPT-cAMPS, suggest-
ing there is no cross-talk involved in the effects of Epac. To ensure
the rigor of our studies and reliability of our findings, we assessed
and confirmed the specificity of the different cAMP analogues we
used in vitro and applied this knowledge in designing functional
ex-vivo contraction studies. Treatment of guinea pig and human
airway smooth muscle cells with the highest functionally effective
concentration of 8-pCPT-2-O-Me-cAMP did not result in the acti-
vation of PKA, as confirmed by its inability to activate the specific
PKA downstream effector VASP. Hence, our data indicate Epac as
an important cAMP effector contributing to relaxation of guinea
pig and human airway smooth muscle tissue.
We also investigated downstream molecular mechanisms that
may underlie Epac-mediated airway smooth muscle relaxation.
Airway smooth muscle tone is controlled by the phosphorylation
level of regulatory MLCs, which permits subsequent actin-myosin
interactions [3]. Interestingly, the methacholine-induced phospho-
rylation of MLC in guinea pig and human airway smooth muscle
cells was completely prevented by concomitant Epac activation.
This is in line with recent findings by Birokuva et al. [27, 28, 48] in
human pulmonary artery endothelial cells showing that activation
of Epac regulates endothelial barrier functioning via inhibition of
MLC phosphorylation and activation of Rac1. Moreover, the
authors described that the reduced phosphorylation of MLC follow-
ing Epac activation was the result of a shift in the balance of 
activity of Rho and Rac towards Rac [28]. Whereas RhoA and
RhoA-activated kinases increase the phosphorylation of MLC either
directly or by inhibition of MLC phosphatase [12, 49], Rac reduces
MLC phosphorylation via activation of p21-activated kinases and
subsequent inhibition of MLC kinase [13]. Interestingly, we demon-
strate here that activation of Epac also shifts the RhoA/Rac1 bal-
ance towards Rac1 in airway smooth muscle cells, as 8-pCPT-2-
O-Me-cAMP inhibited methacholine-induced activation of RhoA in
cultured guinea pig and human airway smooth muscle cells,
whereas it prevented methacholine-induced suppression of Rac1
activation. Taken together, these findings strongly suggest that
Epac-mediated reduction of MLC phosphorylation is the result of
inhibition of methacholine-induced RhoA activation and the preser-
vation of Rac1 activity. The importance of Rac1 activity in 
Epac-mediated airway smooth muscle relaxation was confirmed by
toxicological and pharmacological approaches using the
Clostridium difficile Toxin B-1470 and the Rac1 inhibitor NSC23766,
respectively. Overnight treatment of guinea pig tracheal open rings
with toxin B-1470 reduced the immunoreactivity of Rac1 and
impaired the relaxant effect of Epac towards methacholine-induced
contraction. Although methacholine can reduce Rac1 activity 
in vitro, the treatment of guinea pig airway smooth muscle tissue
with toxin B-1470 did not influence the methacholine-induced tone,
probably due to alternative calcium-dependent mechanisms under-
pinning contraction. In addition, inhibition of Rac1 by NSC23766
completely blocked the inhibitory effect of 8-pCPT-2-O-Me-cAMP
on methacholine-induced phosphorylation of MLC.
Previous studies by Birukova et al. demonstrated an important
role for Rap1 in Epac-mediated activation of Rac1 and subsequent
inhibition of MLC phosphorylation [28]. As we reported recently
© 2011 The Authors
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Fig. 7 Model of Epac-induced airway smooth muscle relaxation. Activation
of Epac by cAMP shifts the balance of RhoA and Rac1 towards Rac1. A
potential mechanism by which Epac affects airway relaxation is repre-
sented by inhibition of MLC phosphorylation. See text for further details.
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that activation of Epac induced GTP-loading of Rap1 in hTERT air-
way smooth muscle cells [29], Epac-dependent activation of Rap1
might contribute to the relaxant properties of Epac on guinea pig
and human airway smooth muscle tone. Importantly, our current
data indicate that Epac-mediated inhibition of methacholine-
induced airway smooth muscle contraction relies on the enforce-
ment of Rac1, which results in impaired MLC phosphorylation. Of
note, Carzola et al. [44] have recently reported that Epac enhances
cardiac contractile function via phosphorylation of contractile 
proteins in freshly isolated adult cardiomyocytes. Thus, it is
tempting to speculate that Epac-dependent cAMP signals con-
tribute to tissue specific 2-agonist functions such as positive
ionotropic properties in the heart and relaxant properties in airway
smooth muscle. We also cannot exclude that Epac signalling to
calcium-dependent potassium channels, calcium channels or
ATP-sensitive potassium channels [46, 47] might also partially
contribute to the relaxant signalling properties of Epac in airway
smooth muscle. However, this does not preclude the strength of
our data collected from a combination of ex vivo and in vitro
experiments in airway tissues of different species. As similar
results were obtained in both guinea pig and human airway
smooth muscle, it is tempting to assume that Epac-mediated shift
of the RhoA/Rac1 balance towards Rac1 and subsequential reduc-
tion of MLC phosphorylation represents a primary effector mech-
anism in airway smooth muscle relaxation. In conclusion, our
present findings show that the cAMP-dependant effector Epac is
an important regulator of airway smooth muscle tone. Given the
relevance of cAMP-driven signalling in the airway pharmacology,
the cAMP-activated Epac-mediated pathway may open new thera-
peutic strategies in the treatment of obstructive airways diseases.
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